Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide

Oncology Reports

Volumn 33, Issue 5, 2015, Pages 2269-2276

  Chen, Ruiling ^a   Wang, Shengchao ^b   Yao, Yunliang ^c   Zhou, Yun ^a   Zhang, Chong ^a   Fang, Jie ^a   Zhang, Dayong ^a   Zhang, Lihuang ^a   Pan, Jianping ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHIHEZI UNIVERSITY   (China)

^c HUZHOU UNIVERSITY   (China)

Author keywords

Anti angiogenic immunotherapy; DNA vaccine; Single chain trimer; VEGFR2

Indexed keywords

DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; BETA 2 MICROGLOBULIN; H2D ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; FEMALE; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MELANOMA; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; CELL LINE; DRUG EFFECTS; EXPERIMENTAL MELANOMA; GENETICS; IMMUNIZATION; IMMUNOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; BETA 2-MICROGLOBULIN; CARCINOMA, LEWIS LUNG; CELL LINE; CELL LINE, TUMOR; HISTOCOMPATIBILITY ANTIGEN H-2D; HUMANS; IMMUNIZATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84927155314     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3820     Document Type: Article

References (38)

1. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438:967-974, 2005.
2. Pan J, Jin P, Yan J and Kabelitz D: Anti-angiogenic active immunotherapy: a new approach to cancer treatment. Cancer Immunol Immunother 57:1105-1114, 2008.
3. Chung AS and Ferrara N: Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 27:563-584, 2011.
4. Potente M, Gerhardt H and Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell 146:873-887, 2011.
5. Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH and Qin LX: MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology 59:1874-1885, 2014.
6. Shojaei F: Anti-angiogenesis therapy in cancer: Current challenges and future perspectives. Cancer Lett 320:130-137, 2012.
7. Croci DO, Cerliani JP, Dalotto-Moreno T, et al: Glycosylationdependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156:744-758, 2014.
8. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E and Faivre S: Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 40:307-319, 2014.
9. Cross MJ and Claesson-Welsh L: FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22:201-207, 2001.
10. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
11. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006.
12. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007.
13. Ren S, Fengyu, Zuo S, Zhao M, Wang X, Wang X, Chen Y, Wu Z and Ren Z: Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine. Vaccine 29:5802-5811, 2011.
14. Bracarda S, Caserta C, Sordini L, Rossi M, Hamzay A and Crinò L: Protein kinase inhibitors in the treatment of renal cell carcinoma: Sorafenib. Ann Oncol 18(Suppl 6):vi22-vi25, 2007.
15. Wei YQ, Wang QR, Zhao X, et al: Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6:1160-1166, 2000.
16. + breast tumors in a mouse model. J Immunol 182:5537-5546, 2009.
17. Zuo SG, Chen Y, Wu ZP, et al: Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. Biol Pharm Bull 33:174-182, 2010.
18. Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P and Hicklin DJ: Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 195:1575-1584, 2002.
19. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J and Gilboa E: Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102:964-971, 2003.
20. Pan J, Heiser A, Marget M, Steinmann J and Kabelitz D: Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination. Gene Ther 12:742-750, 2005.
21. + T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J Immunother 29:32-40, 2006.
22. Hansen T, Yu YY and Fremont DH: Preparation of stable singlechain trimers engineered with peptide, beta2 microglobulin, and MHC heavy chain. Curr Protoc Immunol Chapter 17: Unit 17.15, 2009.
23. Huang CH, Peng S, He L, Tsai YC, Boyd DA, Hansen TH, Wu TC and Hung CF: Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther 12:1180-1186, 2005.
24. Kang TH, Mao CP, La V, Chen A, Hung CF and Wu TC: Innovative DNA vaccine to break immune tolerance against tumor self-antigen. Hum Gene Ther 24:181-188, 2013.
25. Hung CF, Calizo R, Tsai YC, He L and Wu TC: A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 25:127-135, 2007.
26. Huang B, Mao CP, Peng S, He L, Hung CF and Wu TC: Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine 25:7824-7831, 2007.
27. Kim S, Zuiani A, Carrero JA and Hansen TH: Single chain MHC I trimer-based DNA vaccines for protection against Listeria monocytogenes infection. Vaccine 30:2178-2186, 2012.
28. Kim S, Li L, McMurtrey CP, Hildebrand WH, Weidanz JA, Gillanders WE, Diamond MS and Hansen TH: Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol 184:4423-4430, 2010.
29. ∗0201 T-cell epitopes in avian H5N1 viral nucleoprotein induced specific immune responses in HHD mice. Vet Res 41:24, 2010.
30. Cheung YK, Cheng SC, Sin FW, Chan KT and Xie Y: Investigation of immunogenic T-cell epitopes in SARS virus nucleocapsid protein and their role in the prevention and treatment of SARS infection. Hong Kong Med J 14: (Suppl 4): 27-30, 2008.
31. ∗0201 severe acute respiratory syndrome coronavirus epitope. Vaccine 25:6070-6077, 2007.
32. Hu YX, Li M, Jia XH, Du QX, Miao FT, Yao L and Shen JD: HPV16 CTL epitope peptide-activated dendritic cell and natural killer co-culture for therapy of cervical cancer in an animal model. Asian Pac J Cancer Prev 14:7335-7338, 2013.
33. Wang D, Stockard CR, Harkins L, et al: Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem 83:179-189, 2008.
34. Ellis LM and Hicklin DJ: VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591, 2008.
35. Ebos JM, Lee CR and Kerbel RS: Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15:5020-5025, 2009.
36. Yu YY, Netuschil N, Lybarger L, Connolly JM and Hansen TH: Cutting edge: Single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells. J Immunol 168:3145-3149, 2002.
37. Lybarger L, Yu YY, Miley MJ, Fremont DH, Myers N, Primeau T, Truscott SM, Connolly JM and Hansen TH: Enhanced immune presentation of a single-chain major histocompatibility complex class I molecule engineered to optimize linkage of a C-terminally extended peptide. J Biol Chem 278:27105-27111, 2003.
38. Kanagawa N, Yanagawa T, Nakagawa T, Okada N and Nakagawa S: Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy. Cancer Gene Ther 20:57-64, 2013.